Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Growblox Sciences Inc (OP: GBLX )

0.0550 USD -0.0131 (-19.24%)
Official Closing Price Updated: 3:59 PM EST, Mar 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Growblox Sciences Inc

< Previous 1 2 3 4 5 6 Next >
GB Sciences Begins Proof of Concept Studies with Michigan State University for the Treatment of Cytokine Release Syndrome
From ACCESSWIRE
GB Sciences Begins Proof of Concept Studies with Michigan State University for the Treatment of Cytokine Release Syndrome
Tags Healthcare
From Latest Press Releases from Newswire.com
GB Sciences Announces Issuance of US Patent for its Proprietary, Cannabinoid-Based Anti-Inflammatory Formulations
From ACCESSWIRE
GB Sciences Announces Issuance of US Patent for Its Proprietary, Cannabinoid-Based Anti-Inflammatory Formulations
Tags Pharmaceuticals and Biotech
From Latest Press Releases from Newswire.com
GB Sciences Files Provisional Patent Application for the Treatment of Chronic Inflammation Utilizing Its Novel Cannabinoid Containing Complex Mixtures (CCCM)
From ACCESSWIRE
GB Sciences Files Provisional Patent Application for the Treatment of Chronic Inflammation Utilizing Its Novel Cannabinoid Containing Complex Mixtures (CCCM)
Tags Pharmaceuticals and Biotech
From Latest Press Releases from Newswire.com
GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome (ARDS), the Leading Cause of Hospitalization and Deaths, Utilizing Its Cannab
From ACCESSWIRE
GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome (ARDS), the Leading Cause of Hospitalization and Deaths, Utilizing Its Cannab
Tags Pharmaceuticals and Biotech
From Latest Press Releases from Newswire.com
GB Sciences Announces Issuance of US Patent for Its Proprietary Pain Formulations for the 560 Billion Dollar Chronic Pain Treatment Market
From ACCESSWIRE
GB Sciences Announces Issuance of US Patent for Its Proprietary Pain Formulations for the 560 Billion Dollar Chronic Pain Treatment Market
Tags Pharmaceuticals and Biotech
From Latest Press Releases from Newswire.com
GB Sciences Announces Issuance of US Patent for Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease
From ACCESSWIRE
GB Sciences Announces Issuance of US Patent for Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease
Tags Pharmaceuticals and Biotech
From Latest Press Releases from Newswire.com
GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson's Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National
From ACCESSWIRE
GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson's Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National
Tags Pharmaceuticals and Biotech
From Latest Press Releases from Newswire.com
GB Sciences Announces Outstanding Results from Preclinical Study of Its Parkinson's Disease Formulations
GB Sciences, Inc. (OTCQB: GBLX) announced significant preclinical results for their Parkinson's disease ("PD") formulations from the midterm report for their preclinical study being performed by Dr.... 
From PR Newswire
GB Sciences Announces the Sale of The Majority Interest in Nevada Cultivation Operations to Focus on Its First Two Cannabinoid-Based Medical Compounds for Parkinson's Disease and Neuropathic Pain
GB Sciences, Inc. (OTCQB: GBLX) announced the execution of a Binding Letter of Intent for the Sale of 75% of its membership interests in the Company's Las Vegas, Nevada cultivation and production... 
From PR Newswire
Shifting Regulations Open New Doors for the CBD Industry
FinancialBuzz.com News Commentary 
From PR Newswire
OTC Stock Review Features Four CBD Stocks for 2020
With global CBD sales potentially hitting $20 billion by 2024, here are four CBD stocks you'll want to know about 
From GlobeNewswire News Releases
Consumer Spending on Cannabis Grows as More Dispensaries Open Their Doors
FinancialBuzz.com News Commentary 
From PR Newswire
GB Sciences Closes the Sale of GB Sciences Louisiana Cannabis Business to Wellcana Plus and Retains the Benefit of IP Developed Under GB Sciences Louisiana's Master Research and Development Agreement
GB Sciences, Inc. (OTCQB: GBLX) completed the sale on November 15, 2019 of its 50% membership interest in GB Sciences Louisiana, LLC to Wellcana Plus, LLC, an affiliate of Wellcana Group, LLC who owns... 
From PR Newswire
The Closing Date of GB Sciences' Sale of GB Sciences Louisiana LLC Is Delayed
GB Sciences, Inc. (OTCQB: GBLX) announces a delay in the sale of GB Sciences Louisiana LLC. 
From PR Newswire
GB Sciences Welcomes Esteemed Patent and Intellectual Property Attorney, Mr. Edmond DeFrank, to Its Board of Directors
GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce that on October 23rd Mr. Edmond DeFrank joined its Board of Directors, filling a vacant seat. Mr. DeFrank is an attorney in the cannabis sector... 
From PR Newswire
GB Sciences' Chief Science Officer Featured on the Cover of the Marijuana Business Magazine
GB Sciences, Inc. (OTCQB: GBLX) is featured in the October 2019 edition of the Marijuana Business Magazine. This edition (https://mjbizmagazine.com/digital-issues/2019-09-Oct/) examines the evolution... 
From PR Newswire
CannabisNewsBreaks – GB Sciences, Inc. (GBLX) Sells 50% Ownership Stake in GB Sciences Louisiana, LLC
From CannabisNewsWire
CannabisNewsBreaks – GB Sciences, Inc. (GBLX) Sells 50% Ownership Stake in GB Sciences Louisiana, LLC
From InvestorBrandNetwork
GB Sciences Sells Its Louisiana Medical Marijuana Business At A $32 Million Total Valuation
GB Sciences, Inc. (OTCQB: GBLX), on Friday, September 13, 2019, filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC. The stake will be purchased by Wellcana Plus... 
From PR Newswire
U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers
GB Sciences, Inc. (OTCQB: GBLX) today announced that it has received notification from the U.S. Drug Enforcement Agency (DEA) that prior to making any decisions on the pending applications, the DEA... 
From PR Newswire
GB Sciences Names Darin Carpenter as Executive Vice President of Cannabis Operations
GB Sciences, Inc. (OTCQB: GBLX) today announced the appointment to GB Sciences' executive team of Darin Carpenter as the company's new Executive Vice President for Operations and General Manager,... 
From PR Newswire
GB Sciences Prepares To Launch New Products In Louisiana With Educational Seminars For Doctors And Pharmacists
GB Sciences, Inc. (OTCQB: GBLX) announced that its subsidiary GB Sciences Louisiana will hold a series of seminars in August, in partnership with state-approved medical cannabis pharmacies and the LSU... 
From PR Newswire
History Made! GB Sciences Louisiana Announces Medical Cannabis Products Now for Sale for First Time in State History
GB Sciences Louisiana (OTCQB: GBLX) today announced that its medical cannabis products, developed in partnership with LSU AgCenter's Therapeutic Cannabis Program, are available for sale to qualified... 
From PR Newswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.